ZX008 Expanded Access Program-Dravet Syndrome
Brief description of study
The treatment plan for this Expanded Access Protocol is for patients with Dravet syndrome who do not qualify for participation in one of the ongoing ZX008 (fenfluramine hydrochloride) clinical trials. This treatment uses an investigational drug named ZX008, fenfluramine hydrochloride. Investigational means that the Food and Drug Administration (FDA) has not approved the drug for this use. How well this investigational drug works or even if it is safe has not been proven through clinical trials.
Clinical Study Identifier: s19-01402
ClinicalTrials.gov Identifier: NCT03780127
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
